Invivyd (IVVD) Preferred Stock Liabilities (2020 - 2021)
Invivyd's (IVVD) quarterly Preferred Stock Liabilities came in at $504.7 million in Q2 2021, up 197.68% quarter-over-quarter from $169.5 million in Q4 2020.
Powered by 
Analysis
Invivyd (IVVD) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Invivyd (IVVD) has reported Preferred Stock Liabilities for 2 consecutive years, with $504.7 million the latest figure, recorded in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $504.7 million; the trailing twelve-month figure through Jun 2021 stood at $504.7 million (changed N/A YoY), and the FY2020 full-year result was $169.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $504.7 million in Q2 2021 per IVVD's latest filing, from $169.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $504.7 million in Q2 2021 and bottomed at $169.5 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |